DGIdb - SELEGILINE Drug Record

SELEGILINE chembl:CHEMBL972 Approved

Alternate Names:

SELEGILINE
ZELAPAR
EMSAM
ELDEPRYL

Drug Info:

Drug Indications	antiparkinson agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidepressant
Year of Approval	1989
Drug Class	antiparkinson agents

(3 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Patkar et al., 2006, Transdermal selegiline: the new generation of monoamine oxidase inhibitors., CNS Spectr
Lee et al., 2007, Transdermal selegiline for the treatment of major depressive disorder., Neuropsychiatr Dis Treat
Azzaro et al., 2007, Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules., J Clin Pharmacol
Baker et al., 2007, Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?, J Psychiatry Neurosci
Jagrat et al., 2011, Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies., Bioorg. Med. Chem. Lett.
Macleod et al., 2005, Monoamine oxidase B inhibitors for early Parkinson's disease., Cochrane Database Syst Rev
Heinonen et al., 1994, Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites., Clin. Pharmacol. Ther.
Heinonen et al., 1998, Safety of selegiline (deprenyl) in the treatment of Parkinson's disease., Drug Saf
2002, Selegiline: a second look. Six years later: too risky in Parkinson's disease., Prescrire Int
Magyar et al., Pharmacokinetic aspects of deprenyl effects., Pol J Pharmacol Pharm
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Deleu et al., 2002, Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease., Clin Pharmacokinet
Chrisp et al., 1991, Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease., Drugs Aging
Stössel A et al., 2013, Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones., J Med Chem
Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

SELEGILINE MAOB

Interaction Score: 2.9

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Monoamine oxidase B inhibitor

Direct Interaction yes

Trial Name selegiline transdermal,Emsam

PMIDs:
16034956 16641841 7995016 17823646 19300583 9673855 12199263 6441926 17715422 11752352 11978145 1794016 23631427 21680183

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND TTD
SELEGILINE MAOA

Interaction Score: 1.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16641841 19300583 17715422 17823646 21680183

Sources:
DTC
SELEGILINE SLC22A1

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SELEGILINE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
SELEGILINE TACR1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
SELEGILINE CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SELEGILINE CYP3A4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528 22931300

Sources:
DTC PharmGKB
SELEGILINE CYP2C19

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SELEGILINE CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: SELEGILINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class antiparkinson agents

Year of Approval 1989

Publications:
TdgClinicalTrial: SELEGILINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidepressant

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: SELEGILINE

Version: 02-September-2020

Alternate Names:

CHEMBL972 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Jagrat et al., 2011, Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies., Bioorg. Med. Chem. Lett.

Stössel A et al., 2013, Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones., J Med Chem

PharmGKB: selegiline

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics

Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

TTD: Selegiline
- Version: 2020.06.01
Alternate Names:

D0S2UG TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL972
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL972
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Monoamine oxidase B inhibitor
Direct Interaction	yes
Trial Name	selegiline transdermal,Emsam

SELEGILINE Drug Record

SELEGILINE chembl:CHEMBL972 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Monoamine oxidase B inhibitor Direct Interaction yes Trial Name selegiline transdermal,Emsam

PMIDs: 16034956 16641841 7995016 17823646 19300583 9673855 12199263 6441926 17715422 11752352 11978145 1794016 23631427 21680183

Sources: DTC TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16641841 19300583 17715422 17823646 21680183

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9187528 22931300

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: SELEGILINE

Alternate Names:

Drug Info: Drug Class antiparkinson agents Year of Approval 1989

Publications:

TdgClinicalTrial: SELEGILINE

Alternate Names:

Drug Info: Drug Indications antidepressant Drug Class Small Molecule FDA Approval approved

Publications:

DTC: SELEGILINE

Alternate Names: CHEMBL972 ChEMBL Drug ID

Drug Info:

PharmGKB: selegiline

Alternate Names:

Drug Info:

TTD: Selegiline

Alternate Names: D0S2UG TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL972

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL972

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Monoamine oxidase B inhibitor

Direct Interaction yes

Trial Name selegiline transdermal,Emsam

PMIDs:
16034956 16641841 7995016 17823646 19300583 9673855 12199263 6441926 17715422 11752352 11978145 1794016 23631427 21680183

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16641841 19300583 17715422 17823646 21680183

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
9187528 22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Drug Info:

Drug Class antiparkinson agents

Year of Approval 1989

Drug Info:

Drug Indications antidepressant

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

CHEMBL972 ChEMBL Drug ID

Alternate Names:

D0S2UG TTD Drug ID